AARD
Aardvark Therapeutics, Inc. Common Stock
Biotechnology
Market Cap$79M
5Y Perf.-71.4%
Build Your Comparison
Side-by-side financial analysisAARD
RYTM
VNDA
IMVT
CGEM
Try popular comparisons:
Stock Comparison
AARD vs RYTM vs VNDA vs IMVT vs CGEM
Revenue, margins, valuation, and 5-year total return — side by side.
RYTM
Rhythm Pharmaceuticals, Inc.
Biotechnology
Market Cap$6.01B
5Y Perf.+59.6%
VNDA
Vanda Pharmaceuticals Inc.
Biotechnology
Market Cap$361M
5Y Perf.+28.2%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$6.75B
5Y Perf.+59.6%
CGEM
Cullinan Therapeutics, Inc.
Medical - Pharmaceuticals
Market Cap$798M
5Y Perf.+52.9%
AARD vs RYTM vs VNDA vs IMVT vs CGEM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  AARD |  RYTM |  VNDA |  IMVT |  CGEM |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Medical - Pharmaceuticals |
| Market Cap | $79M | $6.01B | $361M | $6.75B | $798M |
| Revenue (TTM) | $0.00 | $217M | $218M | $0.00 | $0.00 |
| Net Income (TTM) | $-70M | $-204M | $-240M | $-506M | $-221M |
| Gross Margin | — | 89.4% | 71.1% | — | — |
| Operating Margin | — | -90.9% | -73.6% | — | — |
| Total Debt | $441K | $246M | $13M | $72K | $3M |
| Cash & Equiv. | $47M | $54M | $85M | $902M | $88M |
AARD vs RYTM vs VNDA vs IMVT vs CGEM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AARD
RYTM
VNDA
IMVT
CGEM
| Stock | Feb 25 | Jun 26 | Return |
|---|---|---|---|
| Aardvark Therapeuti… (AARD) | 100 | 28.6 | -71.4% |
| Rhythm Pharmaceutic… (RYTM) | 100 | 159.6 | +59.6% |
| Vanda Pharmaceutica… (VNDA) | 100 | 128.2 | +28.2% |
| Immunovant, Inc. (IMVT) | 100 | 159.6 | +59.6% |
| Cullinan Therapeuti… (CGEM) | 100 | 152.9 | +52.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AARD vs RYTM vs VNDA vs IMVT vs CGEM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: VNDA leads in 2 of 6 categories (5-stock set), making it the strongest pick for capital preservation and lower volatility and operational efficiency and capital deployment. Rhythm Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion. IMVT and CGEM also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
🥇VNDA emerged as the overall leader. Track its performance:
AARD
Aardvark Therapeutics, Inc. Common Stock
The Healthcare Pick
Among these 5 stocks, AARD doesn't own a clear edge in any measured category.
Best for: healthcare exposure
RYTM
Rhythm Pharmaceuticals, Inc.
The Growth Play
RYTM is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 45.8%, EPS growth 28.3%, 3Y rev CAGR 100.2%
- 45.8% revenue growth vs AARD's -150.9%
Best for: growth exposure
VNDA
Vanda Pharmaceuticals Inc.
The Income Pick
VNDA carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.08
- Lower volatility, beta 1.08, Low D/E 3.9%, current ratio 2.39x
- Beta 1.08 vs AARD's 2.69
- -44.6% ROA vs IMVT's -62.2%
Best for: income & stability and sleep-well-at-night
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT ranks third and is worth considering specifically for long-term compounding.
- 230.5% 10Y total return vs RYTM's 192.2%
- +103.6% vs AARD's -67.8%
Best for: long-term compounding
CGEM
Cullinan Therapeutics, Inc.
The Defensive Pick
CGEM is the clearest fit if your priority is defensive.
- Beta 1.67, current ratio 10.25x
- 5.0% margin vs VNDA's -110.0%
Best for: defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  RYTM | 45.8% revenue growth vs AARD's -150.9% |
| Quality / Margins |  CGEM | 5.0% margin vs VNDA's -110.0% |
| Stability / Safety |  VNDA | Beta 1.08 vs AARD's 2.69 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) |  IMVT | +103.6% vs AARD's -67.8% |
| Efficiency (ROA) | VNDA | -44.6% ROA vs IMVT's -62.2% |
AARD vs RYTM vs VNDA vs IMVT vs CGEM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
Segment breakdown not available.
Segment breakdown not available.
AARD vs RYTM vs VNDA vs IMVT vs CGEM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRYTMLAGGINGCGEM
Who Leads Where
RYTM leads in 2 of 6 categories
AARD leads 0 • VNDA leads 0 • IMVT leads 0 • CGEM leads 0 • 3 tied
Explore the data ↓CGEMCullinan Therapeutics…
0leads
IMVTImmunovant, Inc.
0leads
VNDAVanda Pharmaceuticals…
0leads
AARDAardvark Therapeutics…
0leads
RYTMRhythm Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs AARDvs VNDAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RYTM4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
RYTM3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RYTM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
VNDA and CGEM operate at a comparable scale, with $218M and $0 in trailing revenue. RYTM is the more profitable business, keeping -93.8% of every revenue dollar as net income compared to VNDA's -110.0%. On growth, RYTM holds the edge at +83.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric |  AARDAardvark Therapeu… | RYTMRhythm Pharmaceut… | VNDAVanda Pharmaceuti… | IMVTImmunovant, Inc. | CGEMCullinan Therapeu… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $217M | $218M | $0 | $0 |
| EBITDAEarnings before interest/tax | -$75M | -$196M | -$150M | -$532M | -$240M |
| Net IncomeAfter-tax profit | -$70M | -$204M | -$240M | -$506M | -$221M |
| Free Cash FlowCash after capex | -$62M | -$76M | -$127M | -$407M | -$179M |
| Gross MarginGross profit ÷ Revenue | — | +89.4% | +71.1% | — | — |
| Operating MarginEBIT ÷ Revenue | — | -90.9% | -73.6% | — | — |
| Net MarginNet income ÷ Revenue | — | -93.8% | -110.0% | — | — |
| FCF MarginFCF ÷ Revenue | — | -35.1% | -58.5% | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +83.8% | +3.4% | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -130.2% | -2.5% | -64.0% | -14.1% | -2.4% |
RYTM leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — AARD and RYTM and VNDA each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | AARDAardvark Therapeu… | RYTMRhythm Pharmaceut… | VNDAVanda Pharmaceuti… | IMVTImmunovant, Inc. | CGEMCullinan Therapeu… |
|---|---|---|---|---|---|
| Market CapShares × price | $79M | $6.0B | $361M | $6.8B | $798M |
| Enterprise ValueMkt cap + debt − cash | $33M | $6.2B | $288M | $5.8B | $712M |
| Trailing P/EPrice ÷ TTM EPS | -1.38x | -28.19x | -1.63x | -11.87x | -3.49x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 31.66x | 1.67x | — | — |
| Price / BookPrice ÷ Book value/share | 0.74x | 40.96x | 1.10x | 7.04x | 1.88x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Evenly matched — AARD and RYTM and VNDA each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
Evenly matched — VNDA and IMVT each lead in 3 of 8 comparable metrics.
Profitability & Efficiency
CGEM delivers a -51.5% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-2 for RYTM. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RYTM's 1.77x. On the Piotroski fundamental quality scale (0–9), RYTM scores 5/9 vs CGEM's 1/9, reflecting solid financial health.
| Metric | AARDAardvark Therapeu… | RYTMRhythm Pharmaceut… | VNDAVanda Pharmaceuti… | IMVTImmunovant, Inc. | CGEMCullinan Therapeu… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -61.7% | -2.0% | -61.4% | -68.2% | -51.5% |
| ROA (TTM)Return on assets | -56.3% | -45.2% | -44.6% | -62.2% | -47.6% |
| ROICReturn on invested capital | — | -70.1% | -32.2% | — | -43.5% |
| ROCEReturn on capital employed | -70.0% | -58.9% | -33.6% | -68.3% | -48.2% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 | 2 | 2 | 1 |
| Debt / EquityFinancial leverage | 0.00x | 1.77x | 0.04x | 0.00x | 0.01x |
| Net DebtTotal debt minus cash | -$47M | $192M | -$72M | -$902M | -$86M |
| Cash & Equiv.Liquid assets | $47M | $54M | $85M | $902M | $88M |
| Total DebtShort + long-term debt | $441,000 | $246M | $13M | $72,000 | $3M |
| Interest CoverageEBIT ÷ Interest expense | — | -12.41x | — | — | — |
Evenly matched — VNDA and IMVT each lead in 3 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RYTM leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RYTM five years ago would be worth $45,943 today (with dividends reinvested), compared to $2,544 for AARD. Over the past 12 months, IMVT leads with a +103.6% total return vs AARD's -67.8%. The 3-year compound annual growth rate (CAGR) favors RYTM at 70.5% vs AARD's -36.6% — a key indicator of consistent wealth creation.
| Metric | AARDAardvark Therapeu… | RYTMRhythm Pharmaceut… | VNDAVanda Pharmaceuti… | IMVTImmunovant, Inc. | CGEMCullinan Therapeu… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -72.4% | -16.5% | -26.1% | +26.9% | +28.3% |
| 1-Year ReturnPast 12 months | -67.8% | +35.2% | +33.2% | +103.6% | +44.5% |
| 3-Year ReturnCumulative with dividends | -74.6% | +395.5% | -6.7% | +51.6% | +2.1% |
| 5-Year ReturnCumulative with dividends | -74.6% | +359.4% | -68.2% | +207.0% | -58.6% |
| 10-Year ReturnCumulative with dividends | -74.6% | +192.2% | -43.4% | +230.5% | -56.6% |
| CAGR (3Y)Annualised 3-year return | -36.6% | +70.5% | -2.3% | +14.9% | +0.7% |
RYTM leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — VNDA and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
VNDA is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than AARD's 2.69 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.6% from its 52-week high vs AARD's 20.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AARDAardvark Therapeu… | RYTMRhythm Pharmaceut… | VNDAVanda Pharmaceuti… | IMVTImmunovant, Inc. | CGEMCullinan Therapeu… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.69x | 1.21x | 1.08x | 1.67x | 1.67x |
| 52-Week HighHighest price in past year | $17.94 | $122.20 | $9.94 | $36.27 | $16.74 |
| 52-Week LowLowest price in past year | $3.35 | $60.70 | $4.14 | $14.32 | $5.68 |
| % of 52W HighCurrent price vs 52-week peak | +20.3% | +71.7% | +61.4% | +90.6% | +77.5% |
| RSI (14)Momentum oscillator 0–100 | 32.8 | 45.5 | 41.1 | 51.9 | 32.6 |
| Avg Volume (50D)Average daily shares traded | 155K | 616K | 1.0M | 1.9M | 901K |
Evenly matched — VNDA and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: AARD as "Buy", RYTM as "Buy", VNDA as "Buy", IMVT as "Buy", CGEM as "Buy". Consensus price targets imply 705.8% upside for AARD (target: $29) vs 32.8% for IMVT (target: $44).
| Metric | AARDAardvark Therapeu… | RYTMRhythm Pharmaceut… | VNDAVanda Pharmaceuti… | IMVTImmunovant, Inc. | CGEMCullinan Therapeu… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $29.33 | $140.20 | $14.25 | $43.67 | $31.00 |
| # AnalystsCovering analysts | 8 | 20 | 19 | 23 | 8 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 1 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RYTM leads in 2 of 6 categories — strongest in Income & Cash Flow and Total Returns. 3 categories are tied.
Best OverallRhythm Pharmaceuticals, Inc. (RYTM)Leads 2 of 6 categories
Loading custom metrics...
AARD vs RYTM vs VNDA vs IMVT vs CGEM: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is AARD or RYTM or VNDA or IMVT or CGEM a better buy right now?
For growth investors, Rhythm Pharmaceuticals, Inc.
(RYTM) is the stronger pick with 45. 8% revenue growth year-over-year, versus 8. 7% for Vanda Pharmaceuticals Inc. (VNDA). Analysts rate Aardvark Therapeutics, Inc. Common Stock (AARD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AARD or RYTM or VNDA or IMVT or CGEM?
Over the past 5 years, Rhythm Pharmaceuticals, Inc.
(RYTM) delivered a total return of +359. 4%, compared to -74. 6% for Aardvark Therapeutics, Inc. Common Stock (AARD). Over 10 years, the gap is even starker: IMVT returned +230. 5% versus AARD's -74. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AARD or RYTM or VNDA or IMVT or CGEM?
By beta (market sensitivity over 5 years), Vanda Pharmaceuticals Inc.
(VNDA) is the lower-risk stock at 1. 08β versus Aardvark Therapeutics, Inc. Common Stock's 2. 69β — meaning AARD is approximately 149% more volatile than VNDA relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 177% for Rhythm Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — AARD or RYTM or VNDA or IMVT or CGEM?
By revenue growth (latest reported year), Rhythm Pharmaceuticals, Inc.
(RYTM) is pulling ahead at 45. 8% versus 8. 7% for Vanda Pharmaceuticals Inc. (VNDA). On earnings-per-share growth, the picture is similar: Rhythm Pharmaceuticals, Inc. grew EPS 28. 3% year-over-year, compared to -1068. 8% for Vanda Pharmaceuticals Inc.. Over a 3-year CAGR, RYTM leads at 100. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AARD or RYTM or VNDA or IMVT or CGEM?
Aardvark Therapeutics, Inc.
Common Stock (AARD) is the more profitable company, earning 0. 0% net margin versus -103. 6% for Rhythm Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AARD leads at 0. 0% versus -101. 2% for RYTM. At the gross margin level — before operating expenses — VNDA leads at 94. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AARD or RYTM or VNDA or IMVT or CGEM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AARD or RYTM or VNDA or IMVT or CGEM better for a retirement portfolio?
For long-horizon retirement investors, Rhythm Pharmaceuticals, Inc.
(RYTM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21), +192. 2% 10Y return). Aardvark Therapeutics, Inc. Common Stock (AARD) carries a higher beta of 2. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RYTM: +192. 2%, AARD: -74. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AARD and RYTM and VNDA and IMVT and CGEM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AARD is a small-cap quality compounder stock; RYTM is a small-cap high-growth stock; VNDA is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; CGEM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.